Advanced Prostate Adenocarcinoma
6
2
2
2
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
16.7%
1 terminated out of 6 trials
66.7%
-19.9% vs benchmark
17%
1 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (6)
Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial
Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate Cancer
Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer
Leuprolide Acetate 3.75 mg Depot Injection for Patients With Advanced Prostate Cancer
To Determine an Effective Dose of VERU-100 for the Treatment of Advanced Prostate Cancer
Study to Assess Safety and Tolerability of AZD2171 After Multiple Doses in Patients With Advanced Prostate Cancer